Roderick de Greef chairs Cambridge Heart board

By Mass High Tech Staff

Cambridge Heart licenses MIT heart arrythmia measurement tech [June 23, 2008]

Cambridge Heart partners with Cardiac Science [November 12, 2009]

Cambridge Heart investment takes hit [August 19, 2009]

Promedior plans move to Boston by end of summer [May 23, 2012]

Former chief financial officer of Cambridge Heart Inc., Roderick de Greef, has been appointed chairman of the company’s board of directors, effective immediately. De Greef replaces Kenneth Hachikian, who will continue to serve on the board as lead independent director.

Founded in 1990, Tewksbury-based Cambridge Heart (OTC: CAMH) develops products for non-invasively diagnosing cardiac disease and those potentially at-risk for sudden cardiac arrest. Its tests include the Microvolt T-Wave Alternans Test, which can measure small fluctuations in heartbeat.

De Greef joins the Cambridge Heart board having previously served as executive vice president and CFO of Cardiac Science Inc., which merged with Quinton Cardiology in 2005. He further helps the life sciences sector by sitting on the boards of Endologix Inc. and BioLife Soutions Inc.

De Greef graduated from the University of Oregon with an MBA and from California State University in San Francisco with a bachelor’s degree in economics and international relations.

Cambridge Heart reported quarterly revenue in September of $1.12 million, with a net loss of $2.11 million.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.